MyoKardia Inc. (NASDAQ:MYOK) shares traded up 8.7% during trading on Monday . The stock traded as high as $17.19 and last traded at $16.93, with a volume of 78,766 shares. The stock had previously closed at $15.57.

Several research analysts have recently commented on the company. BMO Capital Markets assumed coverage on MyoKardia in a report on Wednesday, July 20th. They issued an “outperform” rating and a $28.00 price objective on the stock. Zacks Investment Research downgraded MyoKardia from a “hold” rating to a “sell” rating in a report on Wednesday, July 13th. Credit Suisse Group AG reiterated a “buy” rating and issued a $20.00 price objective (up previously from $16.00) on shares of MyoKardia in a report on Tuesday, July 12th. Wedbush reiterated an “outperform” rating and issued a $22.00 price objective on shares of MyoKardia in a report on Thursday, May 12th. Finally, Cowen and Company reiterated a “buy” rating on shares of MyoKardia in a report on Friday, May 13th. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $23.50.

The firm’s market cap is $457.80 million. The stock has a 50 day moving average of $14.14 and a 200-day moving average of $11.22.

MyoKardia (NASDAQ:MYOK) last announced its earnings results on Thursday, May 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.53) by $0.21. Equities analysts predict that MyoKardia Inc. will post ($1.51) EPS for the current fiscal year.

MyoKardia, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in the development of therapies for treating cardiovascular diseases. The Company focuses on developing and discovering therapies for hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.